Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Sellas Life Sciences Group
Merck Sharp & Dohme LLC
AvenCell Therapeutics, Inc.
Caribou Biosciences, Inc.
The Royal Wolverhampton Hospitals NHS Trust
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Chicago
Cedars-Sinai Medical Center
Baylor College of Medicine
Tempus AI
Cancer Research UK
Gamida Cell ltd
University of Miami
Ascentage Pharma Group Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer
Children's Hospital Medical Center, Cincinnati
M.D. Anderson Cancer Center
Center for International Blood and Marrow Transplant Research
Incyte Corporation
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
AbbVie
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
Orca Biosystems, Inc.
Brown University
Institute of Hematology and Blood Transfusion, Czech Republic
UNC Lineberger Comprehensive Cancer Center
VA Office of Research and Development
Pfizer
CellCentric Ltd.
BeOne Medicines
University of Salamanca
University of Florida
National Institutes of Health Clinical Center (CC)
University of Arizona
Cancer Research UK
National Cancer Institute (NCI)
National Cancer Institute (NCI)